She had been an intravenous heroin user in her 20s and had hepatitis C but was HIV negative. She denied use of any other drugs. Results of her neurologic examination were normal except for her involuntary continuous truncal spasms, mostly flexing of her trunk with occasional extension of her pelvis. These occurred when Ms A was sitting or standing but resolved when she lay down. She was also restless when the movements occurred but was relaxed and without movements when lying horizontally. She had mild facial masking and mild bradykinesia and walked without arm-swing. She displayed no choreiform movements.
Aripiprazole treatment was stopped, and Ms A was treated with tetrabenazine 25 mg bid. This caused a mild increase in her parkinsonism and significant benefit in a reduced level of dystonia. This benefit did not persist, however, and 2 months later she was taken off the tetrabenazine. Her dystonia was not signicantly different than at her initial visit.
While there is a general belief that the atypical antipsychotics are associated with fewer extrapyramidal disorders than firstgeneration neuroleptics, the data in support of this are not clear. [5] [6] [7] Parkinsonism has been associated with all of the atypical antipsychotics except quetiapine and clozapine, 8 but there are few data on how common the other disorders, akathisia, acute dystonia, and the tardive syndromes, are in patients not previously treated with neuroleptics. 9 There are few published reports of tardive syndromes occurring with atypical antipsychotics in neuroleptic-naive patients, possibly due to widespread first use of first-generation drugs, possibly due to a lower predisposition to develop a tardive syndrome without prior exposure to a first-generation neuroleptic, or possibly due to less interest by either authors or journals in publishing such cases.
Aripiprazole is a partial dopamine D 2 agonist as well as a serotonin 5-HT 1A agonist and 5-HT 2A antagonist.
10 Yet, it has been found, even at low doses, to worsen motor function in people with Parkinson's disease. 11 The occurrence of a tardive syndrome in a neuroleptic-naive patient clearly implicates the single drug as the cause of the disorder. One possible explanation for the presumed lower incidence of tardive dyskinesia 12 with the second-generation drugs is that the syndrome simply takes longer to develop. These cases, although only 3, 1 argue against this explanation, as all occurred after relatively short exposure to the medication.
As aripiprazole has been approved for treatment of nonpsychotic major depression by the US Food and Drug Administration, and is being advertised for this purpose on television, we may see a marked increase in cases of tardive dyskinesia and parkinsonism. It should be noted that the neuroleptic syndrome has been reported with every atypical antipsychotic, including clozapine. 13 
